Posted: February 19, 2015 at 5:41 am
Stem Cell Therapy Using Bone Marrow - Howard Beach, Ozone Park, Queens NY - Dr. Benjamin Bieber, MD
http://www.crossbaypmr.com Stem Cell Therapy Using Bone Marrow - Howard Beach, Ozone Park, Queens NY - Dr. Benjamin Bieber, MD - Regenerative Medicine Phone:...
By: wpv wpvmedia
See the original post:
Stem Cell Therapy Using Bone Marrow - Howard Beach, Ozone Park, Queens NY - Dr. Benjamin Bieber, MD - Video
Posted: February 18, 2015 at 10:59 pm
13 hours ago The fluorescent probe AIE-MitoGreen-1 reveals changes in mitochondrial organization in brown adipose cells as they mature over the course of a week. Credit: Royal Society of Chemistry
A new cellular labeling strategy gives researchers an efficient tool for studying the development of tissue that could help prevent the onset of obesity and cardiovascular disease.
Most people think about fat in terms of the white adipose tissue that stores the body's excess energy, and which steadilyand visiblyaccumulates as one becomes out of shape or obese. However, there is another type of fat tissue that can prevent rather than promote weight gain. "Brown adipose tissue not only stores fats, but also has the ability to burn fats to release energy as heat," explains Bin Liu of the A*STAR Institute of Materials Research and Engineering.
Liu sees this tissue as a promising target for anti-obesity drugs, and her group set about designing a fluorescent molecule that could help scientists visualize the development of brown adipose cells. These cells can be characterized based on the number and organization of their mitochondria, the organelles that drive cellular metabolism. However, existing mitochondrial dyes tend to absorb each other's fluorescence at high concentrations, resulting in a weaker overall signal as they accumulate.
In collaboration with Hong Kong University of Science and Technology researcher Ben Zhong Tang, Liu's team devised a fluorescent dye that exhibits 'aggregation-induced emission'. "This means that the probe does not emit fluorescence in dilute solutions," explains Liu, "but it becomes highly fluorescent when it accumulates in mitochondria, without any self-quenching effects."
After 20 minutes of treatment with their AIE-MitoGreen-1 probe, Liu's group achieved bright labeling of mitochondria in brown adipose cells that lasted for more than a day. This labeling approach also left cultured cells largely unharmed, whereas only 10 per cent of cells survived prolonged treatment with a commercially available mitochondrial dye. The researchers subsequently used AIE-MitoGreen-1 to monitor the development of brown adipose tissue from precursor cells, observing changes in cell shape and mitochondrial organization over seven days (see image).
Since the basic stages of brown adipose development are well characterized, this probe could help identify treatments that stimulate or impede this process. "We hope to use our probe to monitor the activity of brown adipose cells in response to various stimuli, such as drug intervention or temperature changes," says Liu. Her group aims to further improve their probe so that it shines longer and brighter. Ultimately, she hopes to develop variants that fluoresce at near-infrared wavelengths, which can be detected deeper within living tissue. "We would apply these probes to long-term monitoring of brown adipose cells in animal models."
Explore further: New source of fat tissue stem cells discovered
More information: Gao, M., Sim, C. K., Leung, C. W. T., Hu, Q., Feng, G. et al. A fluorescent light-up probe with AIE characteristics for specific mitochondrial imaging to identify differentiating brown adipose cells. Chemical Communications 50, 83128315 (2014). dx.doi.org/10.1039/c4cc00452c
Researchers have found a new source of stem cells that produce fat tissue, findings presented today at the European Congress of Endocrinology in Wrocaw, Poland, show. This unique in vitro human stem cell model of brown ...
Read the original here:
Fluorescent probe for labeling mitochondria helps scientists study fat-burning brown adipose tissue
Posted: February 18, 2015 at 10:57 pm
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for REVLIMID (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma (NDMM). REVLIMID plus dexamethasone was previously approved in June 2006 for use in multiple myeloma patients who have received at least one prior therapy.
The approval of REVLIMID as an option for use in all patients with multiple myeloma represents a new paradigm in the management of this disease, said Kenneth Anderson, M.D., Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber/Brigham and Womens Cancer Center. We now have clinical evidence demonstrating that starting and keeping newly diagnosed multiple myeloma patients on REVLIMID significantly improves progression-free survival.
The approval was based on safety and efficacy results from phase III studies, including the FIRST trial (MM-020/IFM 07-01), which evaluated continuous REVLIMID in combination with dexamethasone (Rd Continuous) until disease progression versus melphalan, prednisone and thalidomide (MPT) for 18 months as the primary analysis, and a fixed duration of 18 cycles of Rd (Rd18) as a secondary analysis, in 1,623 newly diagnosed patients who were not candidates for stem cell transplant.
In this randomized, open-label, three-arm trial, median progression-free survival (PFS), the length of time a patient lives from study randomization to disease progression or death was the primary endpoint of the study. PFS was significantly longer for patients receiving Rd Continuous (25.5 months) than for those treated with MPT (21.2 months; HR=0.72; p=0.0001). Median overall survival (OS) in the two groups was 58.9 months and 48.5 months, respectively (HR 0.75; 95% CI 0.62, 0.90) based on a March 3, 2014 interim OS analysis. Patients in the Rd Continuous arm had a 25% reduction in the risk of death compared to patients in the MPT arm.
Safety results showed that adverse reactions reported in 20% of NDMM patients in the Rd Continuous, Rd18 or MPT arms included diarrhea (45.5%, 38.5%, 16.5%), anemia (43.8%, 35.7%, 42.3%), neutropenia (35.0%, 33.0%, 60.6%), fatigue (32.5%, 32.8%, 28.5%), back pain (32.0%, 26.9%, 21.4%), insomnia (27.6%, 23.5%, 9.8%), asthenia (28.2%, 22.8%, 22.9%), rash (26.1%, 28.0%, 19.4%), decreased appetite (23.1%, 21.3%, 13.3%), cough (22.7%, 17.4%, 12.6%), pyrexia (21.4%, 18.9%, 14.0%), muscle spasms (20.5%, 18.9%, 11.3%) and abdominal pain (20.5%, 14.4%, 11.1%).
The most frequently reported Grade 3 or 4 events in the Rd Continuous arm (until disease progression) included neutropenia (27.8%), anemia (18.2%), thrombocytopenia (8.3%), pneumonia (11.3%), asthenia (7.7%), fatigue (7.3%), back pain (7%), hypokalemia (6.6%), rash (7.3%), cataract (5.8%), dyspnea (5.6%), DVT (5.6%) and hyperglycemia (5.3%).
At Celgene, we are very happy with the FDAs decision, which adds information on the use of REVLIMID plus dexamethasone as a first-line treatment for multiple myeloma to the prescribing information, said Jacqualyn A. Fouse, Ph.D., President, Global Hematology and Oncology for Celgene. Now, as part of our commitment to improving the lives of patients living with this disease, our next step is to make the benefits of this treatment regimen available to those now eligible under the expanded indication.
Celgene currently has an application under review with the European Medicines Agency (EMA) for approval to use REVLIMID for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. The EMAs Committee for Medicinal Products for Human Use (CHMP) published a positive opinion for this application in December 2014.
About REVLIMID
In the United States, REVLIMID is approved in combination with dexamethasone for the treatment of patients with multiple myeloma. REVLIMID is also approved in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in nearly 70 countries, encompassing Europe, the Americas, the Middle East and Asia, and in combination with dexamethasone for the treatment of patients whose disease has progressed after one therapy in Australia and New Zealand.
See the original post here:
FDA Expands Indication for REVLIMID (Lenalidomide) in Combination with Dexamethasone to Include Patients Newly ...
Posted: February 18, 2015 at 10:49 pm
Contact Information
Available for logged-in reporters only
Newswise While genomics is the study of all of the genes in a cell or organism, epigenomics is the study of all the genomic add-ons and changes that influence gene expression but arent encoded in the DNA sequence. A variety of new epigenomic information is now available in a collection of studies published Feb. 19 in Nature by the National Institutes of Health (NIH) Roadmap Epigenomics Program. This information provides a valuable baseline for future studies of the epigenomes role in human development and disease.
Two of these studies, led by researchers at University of California, San Diego School of Medicine and Ludwig Cancer Research, address the differences between chromosome pairs (one inherited from mom, the other from dad) and how chromosome folding influences gene expression.
Both of these studies provide important considerations for clinicians and researchers who are developing personalized medicines based on a patients genomic information, said Bing Ren, PhD, professor of cellular and molecular medicine at UC San Diego, Ludwig Cancer Research member and senior author of both studies.
The first paper by Rens group takes a look at differences in our chromosome pairs. Each of us inherits one set from our mother and the other from our father. Chromosome pairs are often thought to be identical, one just a backup for the other. But this study found widespread differences in how genes are regulated (turned on and off) between the two chromosomes in a pair. It turns out that we all have biases in our chromosomes. In other words, different traits have a stronger contribution from one parent than the other. The study also suggests that these biases are rooted in inherited sequence variations and that they are not randomly distributed. These findings help explain why, for example, all kids in a family may have their fathers hair but their mothers eyes.
The second paper by Rens group tackles how the genome is organized and how it changes as stem cells differentiate (specialize). DNA strands in every cell are tightly wound and folded into chromosomes. Yet chromosomal structures, and how they influence gene expression, are not well understood. In this study, Ren and team mapped chromosomal structures in stem cells and several different differentiated cell types derived from stem cells. First, they induced differentiation in the stem cells. Then they used molecular tools to examine how the structure of the cells chromosomes changed and how that change is associated with gene activity. The team found that chromosomes are partitioned into relatively stable structural units known as topologically associating domains (TADs), and that TAD boundaries remain constant in different cell types. Whats more, the researchers found that the changes in chromosomal architecture mostly take place within the TADs in a way that correlates with changes in the epigenome.
The epigenome chemical modifications to chromosomes and 3D chromosomal structure is not just a linear object, Ren said. The epigenome is a 3D object, folded in a hierarchical way, and that should affect how we think about many aspects of human development, health and disease.
Co-authors on the paper Integrative Analysis of Haplotype-Resolved Epigenomes Across Human Tissues include Danny Leung, Inkyung Jung, Nisha Rajagopal, Anthony Schmitt, Siddarth Selvaraj, Ah Young Lee, Chia-An Yen, Yunjiang Qiu, Samantha Kuan, Lee Edsall, Ludwig Cancer Research; Shin Lin, Yiing Lin, Stanford University and Washington University School of Medicine; Wei Xie, formerly at Ludwig Cancer Research and now at Tsinghua University; Feng Yue, formerly at Ludwig Cancer Research and now at Pennsylvania State University; Manoj Hariharan, Joseph R. Ecker, Howard Hughes Medical Institute and Salk Institute for Biological Studies; Pradipta Ray, University of Texas; Hongbo Yang, Neil C. Chi, UC San Diego; and Michael Q. Zhang, University of Texas, Dallas and Tsinghua University.
Co-authors on the paper Chromatin Architecture Reorganization during Stem Cell Differentiation include Jesse R. Dixon, Siddarth Selvaraj, Ludwig Cancer Research and UC San Diego; Inkyung Jung, Yin Shen, Ah Young Lee, Zhen Ye, Audrey Kim, Nisha Rajagopal, Yarui Diao, Ludwig Cancer Research; Jessica E. Antosiewicz-Bourget, Morgridge Institute for Research; Wei Xie, Tsinghua University; Jing Liang, Huimin Zhao, University of Illinois at Urbana-Champaign; Victor V. Lobanenkov, National Institute of Allergy and Infectious Diseases; Joseph R. Ecker, Howard Hughes Medical Institute and Salk Institute for Biological Studies; James Thomson, Morgridge Institute for Research, University of Wisconsin and University of California, Santa Barbara.
See the original post here:
New Insights into 3D Genome Organization and Genetic Variability
Posted: February 18, 2015 at 10:43 pm
San Diego, CA (PRWEB) February 18, 2015
San Diego's foremost regenerative medical group, National Institutes for Regenerative Medicine (National IRM) launches complimentary seminars to educate Southern California residents on the revolution of stem cell therapy as an alternative solution for patient's suffering from the most common knee, hip, back or neck pain as well as other arthritic and degenerative conditions. National IRM is an affiliate of the Cell Surgical Network, a collaborative research partner helping to rapidly advance the field and educate the public about Regenerative Medicine.
Regenerative Medicine, commonly referred to as Stem Cell Therapy is a ground-breaking procedure that heals the most common joint and osteoarthritis conditions with human tissue. In a single day, National IRM uses a simple injection of a patient's own Adipose (Adult) stem cells to help regenerate and rebuild almost any joint in the body, increase mobility and allow patients to continue an active, virtually pain-free lifestyle. Initially available only overseas to NFL and NBA athletes and celebrities, National IRM pioneers the most advanced, minimally invasive technology in Southern California's own backyard.
"As we age, the ability to maintain a healthy and active lifestyle is critical for longevity," states Board Certified Plastic Surgeon and National IRM's Chief Medical Officer, Dr. Jon Wilensky. "With age, however a variety of factors inhibit our ability to continue active lifestyles, often in the form of painful, joint related conditions. We're taking a proactive approach to life by offering individuals access to the most advanced Adipose Stem Cell Therapy as an effective alternative to a long and painful recovery typically associated with surgery."
In an effort to reach Southern California residents seeking a solution to chronic, arthritic pain, Dr. Jon Wilensky and The National IRM partnered with Omni La Costa Resort and Spa to offer monthly, complimentary seminars to educate the public on the revolution of stem cell therapy and how this state-of-the-art treatment can help improve longevity and quality of life for candidates suffering from common, joint related conditions, or who may be considering elective surgery due to injury or arthritis.
The next Stem Cell Therapy Seminar will take place Thursday, February 26th from 6:30pm-8:30pm. Registration for the seminar is free and available on National IRM's Seminar website http://explore.nationalirm.com/seminar/
About National IRM National Institutes for Regenerative Medicine (National IRM) is the foremost regenerative medical group in San Diego, CA with a mission to enhance lives by providing the latest advancements in adult stem cell therapy. Through an effective, minimally invasive procedure, National IRM uses uses a patient's own cells, Adipose (Adult) stem cells to help repair some of the world's most common tendon, ligament and bone injuries as well as arthritis. Boasting a team of board-certified specialists, National IRM delivers a multi-disciplinary approach to regenerative medicine, customizing stem cell therapy programs specific to patient's condition to help regenerate and rebuild almost any joint, increase mobility and allow patients to continue an active, virtually pain-free lifestyle.
National IRM is an institutional Review Board (IRB) Approved Research Network. National IRM affiliated with the Cell Surgical Network for the investigational use of SVF for degenerative condition
Here is the original post:
San Diego's Foremost Regenerative Medical Group, National IRM Launches Complimentary, Educational Seminars on Stem ...
Posted: February 18, 2015 at 11:40 am
hepatocyte produced from human leukocytes via retrodifferentiation
Reprogramming leukocyte into endoderm stem cells and subsequent transdifferentiation into hepatocytes. Differentiated hepatocyte fixed with ice cold alcohol and imaged.
By: Ilham Abuljadayel
More here:
hepatocyte produced from human leukocytes via retrodifferentiation - Video
Posted: February 18, 2015 at 11:40 am
Fytofontana Stem Cells rnctalantk
By: Fytofontana Stemcells
Posted: February 18, 2015 at 9:48 am
Contact Information
Available for logged-in reporters only
Newswise When federal funding regulations created limitations on human embryonic stem cell research, several states created their own funding programs. A new study analyzed stem cell funding programs in four states that provided their own funding and found that in both California and Connecticut, state programs have contributed to an increase in the share of publications in the field produced in these states.
The study provides early evidence that the distribution of stem-cell-related publications in the United States differs from the distribution of publications in fields not targeted by specific state funding policies. The study comes at a time when some of these state programs are nearing the final years of their initial funding commitments, so understanding the programs influence on scientific research is important for policy makers and voters.
These state programs have led to more stem cell papers in some cases by a dramatic amount coming out of these states, said Aaron Levine, an associate professor in the School of Public Policy at the Georgia Institute of Technology. Thats important for people to know as they are thinking about whether these programs were a good investment.
The study was started as a project in a class supported by the National Science Foundation (NSF) Stem Cell Biomanufacturing Integrative Graduate Education and Research Traineeship (IGERT) program. The study was published February 6 in the journal Cell Stem Cell.
California, Connecticut, Maryland and New York dedicate state funding to support basic and translational stem cell research, including research on human embryonic stem cells. Similar stem cell funding programs in Illinois and New Jersey have ended, and were not analyzed in the study.
For the study, the researchers examined the share of U.S human embryonic and induced pluripotent stem cell research-related publications with at least one author from California, Connecticut, Maryland, or New York. Those publications were compared to the share of U.S. research papers in other research fields, such as cancer, with at least one author from each state.
Among the states studied, stem cell research in California benefited most from state funding.
California, already a leader in the field, began funding stem cell research in 2006, following a 2004 vote to commit $3 billion to the field. In 2012-2013, 42 percent of U.S. human embryonic stem cell-related research articles had at least one author from California, compared to 18 percent of cancer-related articles and more than half of the human embryonic stem cell-related articles published with at least one California author acknowledged state funding.
Excerpt from:
State Funding Boosts Stem Cell Research in California, Other States
Posted: February 18, 2015 at 9:48 am
MIAMI (PRWEB) February 17, 2015
Regenestem Network, a subsidiary of the Global Stem Cells Group, announced plans to join Charles Mahl, M.D. to open a Regenestem Health Clinic in the historic Westin Colonnade in Coral Gables, Florida. The state-of-the-art clinic will serve as the flagship center for the Regenestem Network and U.S. headquarters for stem cell training courses and patient treatments.
Mahl, a specialist in regenerative medicine, preventive aging medicine and pain therapy, is a member of the Global Stem Cells Group Advisory Board. His recent plans to open a clinic in the spectacular landmark hotel in central Miami lead Mahl to invite Global Stem Cells Group co-founder and Regenestem CEO Ricardo DeCubas to collaborate.
The Westin Colonnade clinic will offer pain, anti-aging and aesthetic regenerative medicine treatments and therapies.
The Regenestem Network is a global family of premier regenerative medicine providers all sharing the same missionto bring the latest in stem cell medicine to patients worldwide. The Regenestem Network is comprised of physicians, medical professionals, researchers, teachers and regenerative medicine product development specialists.
Regenestems commitment to helping improve the quality of life for patients through stem cell therapies makes it a model I wanted to incorporate into the clinic, Mahl says. This collaborative framework will allow us to offer patients promising new stem cell therapies and treatments.
The clinics location within the historic Coral Gables Westin Colonnade in central Miami will welcome patients from across the U.S., Canada, and worldwide. Located just five minutes from the University of Miami, the iconic neoclassical hotel built in the early 20th century that originally served as the offices for Coral Gables intellectual founder George Merrick now serves as a 157-room hotel and hosts a mix of offices and retail space.
According to DeCubas, the clinic will make pain management, anti-aging and aesthetic regenerative medicine treatments readily available to physicians and patients in a clinical setting.
We could not be more pleased or gratified to announce this new shared path of medical and scientific promise with Dr. Mahl and the Coral Gables Community, DeCubas says.
This opens new possibilities for discovery and treatments, and we are proud to work alongside Dr. Mahl to grow Regenestem Health into a cornerstone of patient care that will serve the community for years to come.
View original post here:
Regenestem Network and Charles Mahl, M.D. Launch Regenestem Miami in Westin Colonnade
Posted: February 17, 2015 at 5:52 pm
Human neural stem cell treatments are showing promise for reversing learning and memory deficits after chemotherapy, according to UC Irvine researchers.
In preclinical studies using rodents, they found that stem cells transplanted one week after the completion of a series of chemotherapy sessions restored a range of cognitive functions, as measured one month later using a comprehensive platform of behavioral testing. In contrast, rats not treated with stem cells showed significant learning and memory impairment.
The frequent use of chemotherapy to combat multiple cancers can produce severe cognitive dysfunction, often referred to as "chemobrain," which can persist and manifest in many ways long after the end of treatments in as many as 75 percent of survivors -- a problem of particular concern with pediatric patients.
"Our findings provide the first solid evidence that transplantation of human neural stem cells can be used to reverse chemotherapeutic-induced damage of healthy tissue in the brain," said Charles Limoli, a UCI professor of radiation oncology.
Study results appear in the Feb. 15 issue of Cancer Research, a journal of the American Association for Cancer Research.
Many chemotherapeutic agents used to treat disparate cancer types trigger inflammation in the hippocampus, a cerebral region responsible for many cognitive abilities, such as learning and memory. This inflammation can destroy neurons and other cell types in the brain.
Additionally, these toxic compounds damage the connective structure of neurons, called dendrites and axons, and alter the integrity of synapses -- the vital links that permit neurons to pass electrical and chemical signals throughout the brain. Limoli compares the process to a tree being pruned of its branches and leaves.
Consequently, the affected neurons are less able to transmit important neural messages that underpin learning and memory.
"In many instances, people experience severe cognitive impairment that's progressive and debilitating," Limoli said. "For pediatric cancer patients, the results can be particularly devastating, leading to reduced IQ, asocial behavior and diminished quality of life."
For the UCI study, adult neural stem cells were transplanted into the brains of rats after chemotherapy. They migrated throughout the hippocampus, where they survived and differentiated into multiple neural cell types. Additionally, these cells triggered the secretion of neurotrophic growth factors that helped rebuild wounded neurons.
See the original post here:
Human neural stem cells restore cognitive functions impaired by chemotherapy
